BRUSSELS: Fagron, a global leader in pharmaceutical compounding, reported a 6.4% increase in third-quarter revenue, reaching €228.2 million, and reaffirmed its full-year guidance amid continued momentum across regions and business lines.
Organic growth at constant exchange rates (CER) rose 10.3%, or 8.5% on a normalized basis, with 5.7% growth including the impact of GLP-1-related dynamics. The company cited resilient structural drivers, targeted commercial execution, and strategic acquisitions as key contributors to performance.
CEO Rafael Padilla said the results reflect “the resilience of our model,” highlighting diversified regional growth and operational agility. EMEA showed broad-based gains across Brands, Essentials, and Compounding Services, while Latin America, particularly Brazil, benefited from product launches and increased adoption.
In North America, Fagron’s Wichita facility passed a follow-up FDA inspection with no repeat observations, validating corrective actions and a capacity expansion expected to generate approximately $25 million in additional revenue.
The company also announced antitrust clearance for Purifarma and Injeplast in Brazil, and the signing of University Compounding Pharmacy in the U.S., marking its eighth acquisition this year.
Fagron confirmed its full-year revenue outlook of €930–€950 million and expects a slight year-on-year increase in profitability.